MSRD 100

Drug Profile

MSRD 100

Alternative Names: MSRD-100

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator Merz Pharmaceuticals
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Atopic dermatitis

Most Recent Events

  • 08 Sep 2016 Merz Pharmaceuticals withdraws two phase III trials for Atopic dermatitis (In infants, In children, In adolescents, In adults) in USA (Topical, Gel) (NCT02677610; NCT02677636)
  • 16 Feb 2016 Clinical trials in Atopic dermatitis in Germany (Topical) before February 2016
  • 16 Feb 2016 Merz Pharmaceuticals plans two phase III trials for Atopic dermatitis (In infants, In children, In adolescents, In adults) in USA (Topical, Gel) (NCT02677610; NCT02677636)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top